Portfolio concentration
As of February 28, 2026 · N-PORT
Holdings
263
Top-10 weight
57.92%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
16
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
1054.3
Holdings
As of February 28, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES INC | — | 39,904 | $5.94M | 6.48% |
| 2 | US ULTRA BOND CBT Sep25 | — | 4,291 | $5.82M | 6.34% |
| 3 | VERTEX PHARMACEUTICALS INC | — | 11,581 | $5.75M | 6.27% |
| 4 | AMGEN INC | — | 14,536 | $5.64M | 6.15% |
| 5 | REGENERON PHARMACEUTICALS INC | — | 4,769 | $3.73M | 4.06% |
| 6 | US ULTRA BOND CBT Sep25 | — | 2,484 | $3.31M | 3.61% |
| 7 | US ULTRA BOND CBT Sep25 | — | 2,639 | $2.65M | 2.89% |
| 8 | US ULTRA BOND CBT Sep25 | — | 6,179 | $2.61M | 2.85% |
| 9 | US ULTRA BOND CBT Sep25 | — | 3,646 | $2.41M | 2.63% |
| 10 | ALNYLAM PHARMACEUTICALS INC | — | 6,101 | $2.03M | 2.21% |
| 11 | Invesco Government & Agency Portfolio, Institutional Class | — | 1,662,868 | $1.66M | 1.81% |
| 12 | Repurchase Agreement | — | 1,567,851 | $1.57M | 1.71% |
| 13 | INSMED INC | — | 9,848 | $1.47M | 1.60% |
| 14 | BIOGEN INC | — | 6,774 | $1.30M | 1.42% |
| 15 | ARGENX SE SPONSORED ADR | — | 1,344 | $1.03M | 1.12% |
| 16 | UNITED THERAPEUTICS CORP DEL | — | 1,988 | $1.00M | 1.09% |
| 17 | MODERNA INC | — | 18,039 | $966.35K | 1.05% |
| 18 | ILLUMINA INC | — | 7,055 | $948.62K | 1.03% |
| 19 | ROIVANT SCIENCES LTD | — | 32,114 | $929.38K | 1.01% |
| 20 | INCYTE CORP | — | 9,065 | $918.01K | 1.00% |
| 21 | ROYALTY PHARMA PLC | — | 19,729 | $911.68K | 0.99% |
| 22 | REVOLUTION MEDICINES INC | — | 8,927 | $910.73K | 0.99% |
| 23 | VIATRIS INC | — | 53,183 | $794.02K | 0.87% |
| 24 | Repurchase Agreement | — | 776,976 | $776.98K | 0.85% |
| 25 | Repurchase Agreement | — | 776,976 | $776.98K | 0.85% |
| 26 | Ascendis Pharma A/S | — | 2,835 | $661.97K | 0.72% |
| 27 | NEUROCRINE BIOSCIENCES INC | — | 4,604 | $608.88K | 0.66% |
| 28 | IONIS PHARMACEUTICALS INC | — | 7,479 | $606.92K | 0.66% |
| 29 | SANOFI SPON ADR | SNY US | 12,219 | $594.58K | 0.65% |
| 30 | BRIDGEBIO PHARMA INC | — | 8,897 | $591.47K | 0.64% |
| 31 | MEDPACE HOLDINGS INC | — | 1,301 | $587.74K | 0.64% |
| 32 | SUMMIT THERAPEUTICS INC | — | 34,375 | $570.28K | 0.62% |
| 33 | GUARDANT HEALTH INC | — | 5,974 | $560.96K | 0.61% |
| 34 | BIOMARIN PHARMACEUTICAL INC | — | 8,871 | $547.61K | 0.60% |
| 35 | EXELIXIS INC | — | 12,381 | $545.51K | 0.59% |
| 36 | JAZZ PHARMA PLC | — | 2,806 | $533.20K | 0.58% |
| 37 | BIONTECH SE ADR | — | 4,669 | $514.66K | 0.56% |
| 38 | Repurchase Agreement | — | 466,185 | $466.19K | 0.51% |
| 39 | Repurchase Agreement | — | 466,185 | $466.19K | 0.51% |
| 40 | BEONE MEDICINES LTD ADR | — | 1,454 | $460.90K | 0.50% |
| 41 | MADRIGAL PHARMACEUTICALS INC | — | 1,048 | $452.74K | 0.49% |
| 42 | IMMUNITYBIO INC | — | 45,481 | $444.80K | 0.49% |
| 43 | TEMPUS AI INC-A | — | 7,982 | $425.04K | 0.46% |
| 44 | ARROWHEAD PHARMACEUTICALS INC | — | 6,271 | $396.77K | 0.43% |
| 45 | PRAXIS PRECISION MEDICINES INC | — | 1,155 | $388.95K | 0.42% |
| 46 | Repurchase Agreement | — | 388,488 | $388.49K | 0.42% |
| 47 | AXSOME THERAPEUTICS INC | — | 2,327 | $381.37K | 0.42% |
| 48 | HALOZYME THERAPEUTICS INC | — | 5,430 | $377.55K | 0.41% |
| 49 | VAXCYTE INC | — | 6,044 | $373.16K | 0.41% |
| 50 | KRYSTAL BIOTECH INC | — | 1,339 | $369.08K | 0.40% |
1 / 6
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.